Although most tumors positive for HER2 by immunohistochemistry or by in situ hybridization correspond to the intrinsic HER2-enriched subtype, it is possible to identify any of the remaining intrinsic subtypes in this type of tumor (19, 29, 30). This evidence concerns the gene ERBB2 and neoplasm.